Biopharma bounces back as M&A impetus fuels recovery - Pharmaceutical Technology

In a midyear report, PwC said that a surge in deals eclipsing the billion-dollar mark fuelled M&A momentum. In a midyear report, PwC said that a surge in deals eclipsing the billion-dollar mark fuelled M&A momentum. Modalities such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), RNA therapeutics, and antibody-drug conjugates (ADCs) have been a particular focus of transactions. Credit: Anana_go/Shutterstock.com. Following the largest dealmaking quarter in six years, PwC analysts have empirically stated that the biopharma ecosystem is “back to full health”. In its midyear outlook report, the firm stated that US pharma and life sciences deal value in Q1 2026…

Source: Pharmaceutical Technology